INVA - Innoviva, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
14.11
-0.17 (-1.19%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close14.28
Open14.28
Bid14.12 x 4000
Ask14.13 x 1000
Day's Range14.09 - 14.34
52 Week Range13.07 - 20.54
Volume387,879
Avg. Volume954,248
Market Cap1.429B
Beta (3Y Monthly)0.54
PE Ratio (TTM)3.95
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2015-09-08
1y Target EstN/A
Trade prices are not sourced from all markets
  • Markit12 hours ago

    See what the IHS Markit Score report has to say about Innoviva Inc.

    Innoviva Inc NASDAQ/NGS:INVAView full report here! Summary * Bearish sentiment is moderate and declining * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is moderate for INVA with between 5 and 10% of shares outstanding currently on loan. However, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on June 12. Money flowETF/Index ownership | NeutralETF activity is neutral. The $1.24 billion in inflows that ETFs holding INVA received over the last one-month is a decline from earlier in the period and among the weakest of the past year. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • How Does Innoviva, Inc. (NASDAQ:INVA) Affect Your Portfolio Volatility?
    Simply Wall St.4 days ago

    How Does Innoviva, Inc. (NASDAQ:INVA) Affect Your Portfolio Volatility?

    If you're interested in Innoviva, Inc. (NASDAQ:INVA), then you might want to consider its beta (a measure of share...

  • The Zacks Analyst Blog Highlights: Cambrex, Innoviva, Celgene, BioDelivery Sciences International and Unity Biotechnology
    Zacks23 days ago

    The Zacks Analyst Blog Highlights: Cambrex, Innoviva, Celgene, BioDelivery Sciences International and Unity Biotechnology

    The Zacks Analyst Blog Highlights: Cambrex, Innoviva, Celgene, BioDelivery Sciences International and Unity Biotechnology

  • 5 Biotech Stocks to Gain From Trade Deal Rally on the Horizon
    Zacks24 days ago

    5 Biotech Stocks to Gain From Trade Deal Rally on the Horizon

    Trade-war resistant stocks such as biotechs would be the first to benefit from a relief rally.

  • Earnings Estimates Moving Higher for Innoviva (INVA): Time to Buy?
    Zackslast month

    Earnings Estimates Moving Higher for Innoviva (INVA): Time to Buy?

    Innoviva (INVA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

  • New Strong Buy Stocks for May 15th
    Zackslast month

    New Strong Buy Stocks for May 15th

    New Strong Buy Stocks for May 15th

  • Reuterslast month

    GSK's 3-in-1 inhalable drug shows promise in asthma study

    The company, along with co-developer Innoviva Inc, said the once-daily inhaler improved lung function in patients with uncontrolled asthma, compared to its other medicine Relvar/Breo Ellipta. The results come at a time when GSK is hit by generic competition for its blockbuster asthma treatment Advair and it looks to newer respiratory drugs to make up for declines in older medicines.

  • Associated Presslast month

    Innoviva: 1Q Earnings Snapshot

    The Brisbane, California-based company said it had net income of 31 cents per share. The biopharmaceutical company posted revenue of $55.2 million in the period. Innoviva shares have decreased 20% since ...

  • Is Innoviva, Inc. (INVA) A Good Stock To Buy?
    Insider Monkey2 months ago

    Is Innoviva, Inc. (INVA) A Good Stock To Buy?

    At Insider Monkey we track the activity of some of the best-performing hedge funds like Appaloosa Management, Baupost, and Tiger Global because we determined that some of the stocks that they are collectively bullish on can help us generate returns above the broader indices. Out of thousands of stocks that hedge funds invest in, small-caps […]

  • Those Who Purchased Innoviva (NASDAQ:INVA) Shares Five Years Ago Have A 49% Loss To Show For It
    Simply Wall St.2 months ago

    Those Who Purchased Innoviva (NASDAQ:INVA) Shares Five Years Ago Have A 49% Loss To Show For It

    In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market index fund. But every investor is virtually certain to have both over-performing and under-performing stocks...

  • 3 Top Biotech Stocks to Buy in April
    Motley Fool2 months ago

    3 Top Biotech Stocks to Buy in April

    These three biotech stocks are worth buying this month.

  • How Many Insiders Bought Innoviva, Inc. (NASDAQ:INVA) Shares?
    Simply Wall St.3 months ago

    How Many Insiders Bought Innoviva, Inc. (NASDAQ:INVA) Shares?

    We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also plenty of examples of share prices declining precipitously after insidersRead More...

  • GuruFocus.com4 months ago

    Innoviva Inc (INVA) Files 10-K for the Fiscal Year Ended on December 31, 2018

    Innoviva Inc (NASDAQ:INVA) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018.

  • Moody's4 months ago

    Innoviva, Inc. -- Moody's announces completion of a periodic review of ratings of Innoviva, Inc.

    Announcement: Moody's announces completion of a periodic review of ratings of Innoviva, Inc. New York, February 15, 2019 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Innoviva, Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.

  • Buy the Dip on This Pharma Stock
    Schaeffer's Investment Research4 months ago

    Buy the Dip on This Pharma Stock

    The stock just pulled back to a trendline with bullish implications

  • Associated Press4 months ago

    Innoviva: 4Q Earnings Snapshot

    On a per-share basis, the Brisbane, California-based company said it had profit of $2.34. The biopharmaceutical company posted revenue of $79.9 million in the period. For the year, the company reported ...

  • Mylan Pops After FDA Approves Its Knockoff Of Glaxo's Asthma Inhaler
    Investor's Business Daily4 months ago

    Mylan Pops After FDA Approves Its Knockoff Of Glaxo's Asthma Inhaler

    Mylan stock popped late Wednesday after the Food and Drug Administration approved its generic version of GlaxoSmithKline asthma inhaler Advair. Mylan shares rose 7%.